Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Pfizer
Takeda
Gustave Roussy, Cancer Campus, Grand Paris
Bolt Biotherapeutics, Inc.
Tempus AI
Actym Therapeutics, Inc.
Bolt Biotherapeutics, Inc.
Elevation Oncology
Aminex Therapeutics, Inc.
Inhibrx Biosciences, Inc
Novartis
Pfizer
Ikena Oncology
Merck Sharp & Dohme LLC
Fate Therapeutics
Fate Therapeutics
Hoffmann-La Roche
Rubius Therapeutics
Montefiore Medical Center
Merck Sharp & Dohme LLC
Case Comprehensive Cancer Center
Tocagen Inc.
University of Wisconsin, Madison
CureOne
Georgetown University
sigma-tau i.f.r. S.p.A.
Instituto do Cancer do Estado de São Paulo
Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC
Stanford University
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
University of Wisconsin, Madison
Lotung Poh-Ai Hospital